Cargando…
Venlafaxine extended release (XR) in the treatment of panic disorder
Panic disorder is a chronic, recurrent illness, with a lifetime prevalence of about 5%. It is associated with substantial functional impairment, and studies suggest that treatment with medication alone (and no instruction in exposure to feared and avoided situations) is less than optimal. In fact, 4...
Autores principales: | Kjernisted, Kevin, McIntosh, Diane |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936289/ https://www.ncbi.nlm.nih.gov/pubmed/18360616 |
Ejemplares similares
-
Venlafaxine in the treatment of panic disorder
por: Katzman, Martin A, et al.
Publicado: (2007) -
A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal
por: Silva Miguel, Luís, et al.
Publicado: (2013) -
A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder
por: Goddard, Andrew W., et al.
Publicado: (2015) -
Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013) -
Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom
por: Shi, Nianwen, et al.
Publicado: (2012)